title: Vorapaxar for the reduction of atherothrombotic events.
abstract: Vorapaxar is a novel platelet inhibitor that potently and selectively inhibits thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen via antagonism of the platelet proteinase-activated receptor PAR1. Vorapaxar is a non-peptide himbacine analogue that has been developed for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.
authors.affiliation: Hemotherapy-Hemostasis Department, CDB, Hospital Clínic, University of Barcelona, Barcelona, Spain. mdiaz@clinic.ub.es.
authors.forename: M
authors.initials: M
authors.lastname: Diaz-Ricart
authors.affiliation: Hemotherapy-Hemostasis Department, CDB, Hospital Clínic, University of Barcelona, Barcelona, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Escolar
mesh_terms: D004347:Drug Interactions; D018565:Food-Drug Interactions; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C530299:vorapaxar
keywords: Coronary artery disease; Metastatic bone disease; Myocardial infarction; PAR1 antagonists; Stroke; Vorapaxar